Last updated: February 24, 2026
What is the Drug with NDC 66794-0228?
The drug identified by NDC 66794-0228 is Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy manufactured by Novartis. Approved by the FDA in May 2019, Zolgensma treats spinal muscular atrophy (SMA) type 1 in pediatric patients under two years old. It is administered as a one-time intravenous infusion.
Market Overview
Disease & Treatment Landscape
- Spinal muscular atrophy (SMA) is a genetic disorder characterized by progressive muscle weakness and atrophy.
- The disease affects approximately 1 in 10,000 live births globally, with higher prevalence in certain populations.
- Existing treatments before Zolgensma included Spinraza (nusinersen) and Evrysdi (risdiplam).
Competitive Position
| Product |
Type |
Approval Year |
Price (per dose/year) |
Market Share (2022) |
| Zolgensma |
Gene therapy |
2019 |
$2.1 million (single dose) |
Leading in new patient initiations |
| Spinraza |
Antisense oligonucleotide |
2016 |
$750,000 (initial, per dose) |
Largest cumulative revenue |
| Evrysdi |
Oral SMN2 splicing modifier |
2019 |
$330,000/year |
Gaining market share |
Note: Actual prices can vary based on insurance, rebates, and negotiating factors.
Market Drivers
- Increasing diagnosis rates, driven by newborn screening programs.
- Expanding age eligibility in some regions.
- High unmet medical need for severe SMA types.
Market Challenges
- High drug price prompting payer resistance.
- Limited patient population due to rarity.
- Manufacturing complexities of gene therapies.
Price Development & Trends
Initial Pricing
- Zolgensma debuted with a list price of $2.1 million per dose, making it one of the most expensive drugs on the market.
- Justification includes manufacturing costs, the one-time administration, and the high cost of R&D.
Price Trends
- Prices for gene therapies like Zolgensma have remained stable but face pressure from payers.
- Recent negotiations and value-based pricing initiatives could influence future discounts.
Payer Dynamics
- Payers favor outcome-based contracts, considering the long-term benefits versus upfront costs.
- Some reimbursement agreements include outcome-based rebates or installment payments.
Market Forecasts
Revenue Projections (2023-2028)
| Year |
Expected US Revenue |
Global Revenue |
Notes |
| 2023 |
$920 million |
$1.2 billion |
Increasing adoption, expanded indications expected |
| 2024 |
$1.05 billion |
$1.4 billion |
Expanded newborn screening, new biosimilar policies in some markets |
| 2025 |
$1.2 billion |
$1.6 billion |
Entry into additional markets, pricing negotiations |
| 2026 |
$1.35 billion |
$1.8 billion |
Growing global acceptance, healthcare system integration |
| 2027 |
$1.5 billion |
$2 billion |
Competitive pressures from upcoming therapies |
| 2028 |
$1.6 billion |
$2.2 billion |
Market maturity, potential patent expirations |
Assumptions
- Steady uptake driven by expanded newborn screening programs.
- No significant price reductions; price remains close to initial levels.
- Regulatory approvals for broader pediatric indications are granted.
- Manufacturing capacity scales to meet global demand.
Potential Price Adjustments and Market Factors
- Price reductions of 10-20% over the next five years are plausible due to payer negotiations.
- Market entry of biosimilars or follow-on gene therapies could pressure pricing.
- Advances in alternative treatments or combination therapies may alter the competitive landscape.
Regulatory & Policy Impact
- Governmental initiatives aim to contain costs for rare disease treatments.
- Some countries implement risk-sharing agreements, influencing net pricing.
- Patent protections expiration expected around 2028-2030, potentially leading to biosimilar market entries.
Key Takeaways
- NDC 66794-0228 (Zolgensma) is a high-cost, first-in-class gene therapy for SMA, with continuation of its premium price justified by its one-time administration and high unmet need.
- The global market is expected to grow to over $2 billion by 2028, driven by increased diagnosis, expanded indications, and improved reimbursement arrangements.
- Price pressures are likely, especially with biosimilar developments and healthcare cost containment efforts.
- Payer strategies, outcomes-based contracts, and policy changes will significantly influence actual market revenue and price adjustments.
FAQ
Q1: What factors could lead to a reduction in Zolgensma's price?
Reimbursement negotiations, biosimilar competition, and regulatory policies prioritizing cost containment could lower net prices.
Q2: How does Zolgensma compare to other SMA treatments?
Zolgensma offers a single-dose administration, while Spinraza and Evrysdi require ongoing dosing. Pricewise, Zolgensma's upfront cost exceeds that of competitors, but it may be cost-effective over the long term depending on outcomes.
Q3: Are there pending regulatory changes affecting Zolgensma?
While no major regulatory changes are announced for pricing, expanded indications and new approvals could impact market size and reimbursement policies.
Q4: How is the global market segmented for Zolgensma?
The U.S. accounts for the largest share due to early adoption and strong newborn screening programs. Europe and Asia-Pacific are expanding rapidly with new approvals and diagnostics.
Q5: What are the primary risks for market growth?
Development of competing therapies, biosimilars, or gene editing breakthroughs; pricing pressures; and restrictions on payer funding could limit revenue growth.
Sources:
- Food and Drug Administration. (2019). FDA approves Zolgensma for children less than 2 years old.
- IQVIA. (2022). The Global Use of Medicine Report.
- Novartis. (2023). Zolgensma product information and financial disclosures.
- Center for Disease Control and Prevention. (2021). SMA newborn screening guidelines.
- EvaluatePharma. (2023). Annual report on rare disease therapies.
[1] FDA. (2019). Zolgensma FDA approval announcement.
[2] IQVIA. (2022). The Use of Medicines Report.
[3] Novartis. (2023). Zolgensma commercial data.
[4] CDC. (2021). SMA screening initiatives.
[5] EvaluatePharma. (2023). Rare disease market analysis.
